Full TitlePhase 2 Study of Tafasitamab and Lenalidomide in Relapsed or Refractory Mantle Cell Lymphoma
The purpose of this study is to assess the safety and effectiveness of combining tafasitamab with lenalidomide for people with mantle cell lymphoma (MCL) that has come back or continued to grow despite treatment. Lenalidomide is a standard MCL treatment and helps change or control the function of the immune system. Tafasitamab is an antibody. When it binds to the CD19 protein on lymphoma cells, it can cause an immune response that damages lymphoma cells by attracting immune cells. The immune cells then release molecules that can kill the lymphoma cells.
Giving tafasitamab with lenalidomide may be more effective than either drug given alone. Tafasitamab is given intravenously (by vein) and lenalidomide is taken orally (by mouth).
Who Can Join
To be eligible for this study, patients must meet several requirements, including:
- Participants must have MCL that has come back or continued to grow despite treatment.
- Patients must be physically well enough that they are able to be mobile, take care of themselves, and engage in all but physically strenuous activities. For example, they must be well enough that they could carry out office work or light housework.
- This study is for people age 18 and older.
For more information and to ask about eligibility for this study, please contact the office of Dr. Anita Kumar at 646-608-3780.